Onconic’s JAQBO (zastaprazan citrate) received Korea’s MFDS approval, based on comprehensive data of P-III study from 28 sites of Korea presented at UEG in Oct’23. Data shown effectiveness on erosive esophagitis with 97.9% healing rate, after 8wks
Launch of JAQBO is expected in 2024, following its Korean National Healthcare Insurance Reimbursement listing. Jeil Pharmaceutical (Onconic’s parent company) will be responsible for JAQBO’s domestic sales
In Mar’23, Livzon Pharmaceutical acquired a license to use JAQBO in China for total transaction value of $127.5 million
Ref: Onconic Therapeutics | Image: Onconic Therapeutics
Related News:- Phanthom Pharmaceutical Receives the US FDA Approval for Vaquenza (vonoprazan) for the Treatment of Erosive GERD
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
